Barrington Research Reiterates Buy Rating for CNXC
Barrington Research maintains a buy rating on CNXC with a $38 price target, a 51.52% upside from the current price.
Key Points
- On June 22, 2026, Barrington Research reiterated its buy rating on CNXC, setting a price target of $38.
- Barrington Research's $38 price target implies 51.52% upside from Concentrix Corporation's ($CNXC) current $25.08 share price.
- Shares of CNXC traded at $25.08 on Monday, reflecting ongoing interest in the stock.
- Groupe Bruxelles Lambert held steady in CNXC, while AQR Capital Management increased its stake by 1.88 million shares.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Barrington Research has reiterated its buy rating on CNXC, setting a price target of $38. This update came on June 22, 2026, as the firm continues to show confidence in the company's potential. On the same day, CNXC's stock traded at $25.08.
Other Institutional Activity in CNXC
Groupe Bruxelles Lambert maintained its position in CNXC with 8,773,667 shares valued at approximately $240.05 million. Meanwhile, AQR Capital Management increased its holdings by 1,881,581 shares, bringing its total to 4,831,868 shares worth about $132.20 million, marking a 63.8% increase. FMR LLC also boosted its stake by 1,414,243 shares, reaching 4,223,282 shares valued at $115.55 million, a 50.3% increase. BlackRock, Inc. added 235,325 shares, now holding 4,062,197 shares worth $111.14 million, a 6.1% rise. Dimensional Fund Advisors LP grew its position by 460,108 shares to a total of 2,951,378 shares, valued at $80.75 million, reflecting an 18.5% increase.
Insider Buying and Selling at Concentrix Corporation
On April 29, 2026, Groupe Bruxelles Lambert sold 6,000,000 shares at an average price of $22.25. On the buying side, Valentine Andre, the Chief Financial Officer, purchased 2,500 shares on April 9, 2026, at $27.95 each. Earlier, on March 26, 2026, Christopher Caldwell, the President and CEO, acquired 1,000 shares at $26.97 per share. Additionally, on March 25, 2026, Laverne Council, Jennifer Deason, and Kathryn Hayley each bought 7,701 shares.
Analysts Set New Price Targets
On June 22, 2026, Barrington Research maintained its buy rating on CNXC with a price target of $38. Previously, Canaccord Genuity and Baird also maintained buy ratings, with Canaccord setting a target of $55 and Baird at $40 on March 25, 2026. The consensus among analysts is positive, with a general buy recommendation.
Bottom Line
Barrington Research's reiterated buy rating and $38 price target suggest ongoing confidence in CNXC. Institutional investors like AQR Capital Management and FMR LLC have increased their stakes, indicating a strong interest in the company's prospects. Insider activities also highlight varied movements within the company. This analyst update provides a snapshot of the market's sentiment towards CNXC as of June 2026.
Get Concentrix Corporation alerts
New 13F filings, insider trades, and analyst moves on $CNXC, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.